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Case Report
“FLU” SYNDROME ASSOCIATED WITH OTHER SYSTEMIC
MANIFESTATIONS WITH ONCE A MONTH RIFAMPICIN IN THE
TREATMENT OF MULTIBACILLARY LEPROSY
A Thomas, P Joseph and R Prabhakar
Rifampicin, a potent bactericidal drug, has become an essential component
       of multidrug treatment regimens for tuberculosis and leprosy. One of the adverse
reactions described following twice weekly or once weekly administration of
rifampicin is the “‘Flu” syndrome (Sister Mary Aquinas et al 1972, Girling &
Wallace 1971). This syndrome is immunological in nature and is often associated
with the presence of circulating rifampicin - dependent anti-bodies (Riska &
Mattson 1972, Proceedings of Workshop 1973). Initially it was thought to be
uncommon with longer intervals between doses of the drug, i.e., once a month
administration, as advocated in the chemotherapy of leprosy (WHO 1982).
However, there have been a few reports about the occurrence of “Fl ” syndrome
with a regimen containing rifampicin once a mouth (Naafs & Matemera 1986,
Parking & Shah 1989, Patki et al 1988, Vaz et al 1989). We report here three
cases of leprosy developing “Flu” syndrome, associated with other systemic
manifestations, during the monthly phase of their treatment
CASE REPORTS
CASE 1
A 45-year old male suffering from subpolar lepromatous leprosy
with a bacterial index (BI) of 3.67 was prescribed a regimen of rifampicin,
clofazimine and dapsone. Rifampicin 600 mg was given daily for three months,
twice a week from the fourth to 12th month and once a month from 13 to 24
months. During the monthly phase the patient gave the history that after the
second monthly dose of rifampicin, he had developed fever with severe chills and
rigors, malaise, giddiness, vomiting and diarrhoea. The above mentioned
symptoms appeared approximately one and half to two hours after the
administration of drugs and gradually subsided by 24 hours.
Dr A Thomas
Dr P Joseph
* Dr R Prabhakar
Tuberculosis Research Centre, Spurtank Road, Madras 600 031.
* Correspondence and reprint requests
219
Indian J Lepr VoL65(2) 1993
This recurred after the the third and fourth monthly dose also. However, the
patient reported this problem to the treating physician only after the fourth
monthly dose. In the clinic, the patient was observed after administration of
rifampicin under supervision in the same dosage. The temperature was recorded
as 98.4° F before giving the drug. After one and half hours he developed chills,
rigors and giddiness. His temperature rose to 99.4° F accompanied by severe
body ache and vomiting. The patient was given a corticosteroid preparation
(Decadron•) and the antihistamine pheneramine maleate, which resulted in the
subsidence of symptoms. Rifampicin was terminated and the treatment was    
continued with clofazimine and dapsone, and the patient’s progress then onwards
was uneventful.
CASE 2
A female aged 40 years suffering from borderline lepromatous
leprosy with a BI of 4.50 was prescribed a regimen of rifampicin, clofazimine,
dapsone and pyrazinamide. Rifampicin was given in a dosage of 450 mg, and the
scheme of administration was similar to that for case I. She also complained of
fever with chills and rigors associated with severe body ache and diarrhoea after
approximately one and half to two hours of the monthly dose of rifampicin. The
first episode was reported to have occurred after the fourth monthly dose of
rifampicin. The symptoms recurred in the following month also but, she had not
reported them as she did not associate the problem with ingestion of the drug. She
absented herself for the next two months (sixth and seventh month). When she
attended for the eighth monthly treatment, rifampicin was administered and the
following day she was hospitalised. She was diagnosed as having viral hepatitis
and was treated for the same. Her liver function test (LFT) results were as
follows: total bilirubin 3 mg/dl, AST 160 units/ml, ALT 120 units/ml and bile      
pigment was found in the urine. She was discharged after a week.
The LFT was repeated subsequently and the values were within normal
limits. It was after the tenth monthly dose of rifampicin when she again
developed fever with chills and rigors and diarrhoea and again she had reported to
the clinic for the same, that a diagnosis of “Flu” syndrome was made. Rifampicin
was immediately withdrawn.
CASE 3
A 25-year old male suffering from subpolar lepromatous leprosy
with BI of 4.67 was prescribed the above mentioned regimen and dosage scheme
was as for case I. After having the ninth monthly dose of rifampicin the patient
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developed fever and vomiting lasting for a few hours on the same day, followed
by oliguria of 48 hours duration. The patient attended the clinic on the third day.
On examination the patient appeared pale with a haemoglobin level of 10 gm%.
His blood pressure was 150/90mm Hg. He was passing dark coloured urine and
clinical pathology examination revealed trace of albumin with one to three pus
cells/high power field along with RBCs and a large number of hyaline and
epithelial casts. Blood urea and creatinine values were 220mg/dl and 13 mg/dl,
respectively. On questioning, the patient gave a history of pyrexial attacks for the
past four to five months and the fever used to come about two hours after
rifampicin administration. Since he used to get better by the same evening he
never reported the matter to the clinic. After two days of the latest episode the
blood urea and creatinine values were 226mg/dl and 16 mg/dl, respectively, but
the patient was feeling better symptomatically. The patient’s urine output
increased by fourth day. He was admitted in a nephrology ward and was treated
on conservative lines. After two weeks his blood urea and creatinine levels had
decreased considerably, to 66 mg/dl and 1.3 mg/dl, respectively. In view of his
symptoms suggestive of “Flu” syndrome, administration of rifampicin was
terminated. The patient was being treated for ENL reaction also and his reaction
was brought  under control with steroids.
A total of 40 cases were being treated with the above mentioned rhythm of
rifampicin of which three patients developed “Flu” syndrome.
COMMENTS
Rifampicin, a powerful bactericidal drug, was introduced in the treatment of
tuberculosis in the late sixties. Intermittent administration of rifampicin was
initiated around 1969, and a new type of reaction was reported (Poole et al 1971)
which was termed ‘systemic reaction’ and its association with rifampicin anti-
body formation was discovered subsequently (Poole et al 1971, Riska & Mattson
1972. Proceedings of Workshop 1973). This was followed by reports by various
workers (Girling & Wallace 1971, Mattson 1973. Sister Mary Aquinas et al 1972)
describing various syndromes such as “Flu” syndrome, abdominal syndrome,
respiratory syndrome, cutaneous syndrome and haemolytic syndrome, all
associated with intermittent rifampicin administration.
Various animal experiments followed by clinical trials showed that in the
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chemotherapy of leprosy, rifampicin administered once month was as effective as
daily, twice a week, or, once a week administration of the drug (Levy et al 1976).
“Flu” syndrome was not reported in the earlier period of multidrug therapy
(MDT) with once a month regimen of rifampicin (Opromolla et al 1981, Girdhar
& Dcsikan 1979, Girling & Hitze 1979, Languillon et al 1979, WHO 1982).
However. since then a few workers have reported its occurrence even with the
administration of once a month rifampicin (Naafs & Matemera 1986, Parking &
Shah 1989, Patki et al 1988, Vaz et al 1989).
It has been reported that a higher dosage (900-1200 mg) of rifampicin given
intermittently precipitated “Flu” syndrome (Girling & Hitze 1979, Pujet et al
1974, Sister Mary Aquinas et al 1972) and that reduction of dosage to 450-600
mg resulted in disappearance of symptoms. In the present series, the patients were
receiving rifampicin 12 mg/kg body weight from the beginning, which amounted
to a flat dose of 450-600 mg and yet they developed symptoms suggestive of
“Flu” syndrome in association with other systemic manifestations. Similarly, it
has also been reported that “Flu” syndrome was was common if intermittent
rifampicin administration was preceded by a period of daily administration (Hong
Koug Tuberculosis Treatment Services 1974, Vaz et al 1989). However, all the
three of our patients who developed “Flu” syndrome had in fact received daily
rifampicin for three months before the intermittent administration of the drug was
intiated. “Flu” syndrome as has been described by several workers (Patki et al
1988, Vaz et al 1989) is not usually serious enough to warrant termination of
rifampicin, since it can be controlled with analgesics and antipyretics. In our
experience, as illustrated in these three cases, the syndrome could manifest with
more systemic features (abdominal, hepatic reaction, renal failure) which may on
occasions be life threatening, warranting termination of rifampicin. Various
recent reports (Naafs & Matemera 1986, Parking & Shah 1989, Patki et al 1988,
Vaz et al 1989) have shown that monthly dose of rifampicin is not completely
free from side effects and it is evident that the medical and the paramedical
workers in the field should be aware of this fact while treating leprosy patients
with MDT in the programme.
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